Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 11/20 | 0.58 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.58 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | PTPRB | P23467 | 1/20 | 0.46 |
| ▸ | CDC25A | P30304 | 1/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.46 |
| ▸ | PTEN | P60484 | 1/20 | 0.46 |
| ▸ | PTPMT1 | Q8WUK0 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7015990 | 0.91 | FFAR1 (0.51) | FFAR1FFAR4KEAP1PTPRBCDC25A | |
| SCHEMBL6954266 | 0.89 | CYP1A2 (0.57) | FFAR1FFAR4 | |
| SCHEMBL7017733 | 0.87 | FFAR1 (0.51) | FFAR1FFAR4KEAP1 | |
| Hydrochloric Acid SCHEMBL7358774 | 0.87 | CYP1A2 (0.56) | FFAR1FFAR4 | |
| SCHEMBL30428461 | 0.87 | MAPT (0.55) | FFAR1FFAR4 | |
| SCHEMBL3578367 | 0.86 | IAPP (0.49) | FFAR1FFAR4 | |
| SCHEMBL10277036 | 0.85 | MAPT (0.58) | FFAR1FFAR4 | |
| SCHEMBL30782466 | 0.85 | FFAR1 (0.55) | FFAR1FFAR4KEAP1PTPRBCDC25A | |
| SCHEMBL3336184 | 0.85 | FFAR1 (0.55) | FFAR1FFAR4KEAP1PTPRBCDC25A | |
| SCHEMBL4815073 | 0.83 | FFAR1 (0.51) | FFAR1FFAR4KEAP1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140179-A2 | USE OF A CYCLOOXYGENASE 2 INHIBITOR AND AN INTEGRIN ANTAGONIST AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2000038786-A2 | USE OF CYCLOOXYGENASE 2 INHIBITOR AND AN INTEGRIN ANTAGONIST AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | claimed |
| US-12404265-B2 | Substituted pyridine derivatives as SARM1 inhibitors | NURA BIO, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-12037333-B2 | Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication | COCRYSTAL PHARMA, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037333-B2 | Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication | COCRYSTAL PHARMA, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037333-B2 | Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication | COCRYSTAL PHARMA, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240199591-A1 | SELECTIVE LIGANDS FOR MODULATION OF GIRK CHANNELS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2024-06-20 | — | — | US | disclosed |
| US-11999695-B2 | YAP1 inhibitors that target the interaction of YAP1 with OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-11970481-B1 | Substituted pyridine derivatives as SARM1 inhibitors | NURA BIO, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| US-20240116901-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | NURA BIO, INC. | 2024-04-11 | — | — | US | disclosed |
| US-11952370-B2 | Selective ligands for modulation of GIRK channels | NORTHEASTERN UNIVERSITY (US) | 2024-04-09 | — | — | US | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2001025203-A1 | PYRIDINE CARBOXAMIDE OR SULFONAMIDE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-04-12 | — | — | WO | disclosed |
| WO-2000059503-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-10-12 | — | — | WO | disclosed |
| WO-2000038786-A2 | USE OF CYCLOOXYGENASE 2 INHIBITOR AND AN INTEGRIN ANTAGONIST AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| US-5719280-A | REACTING AMINE SUBSTITUTED BENZOCYCLOALKANE WITH DIALKYLOXYACETALDEHYDE IN PRESENCE OF REDUCING AGENT OR CATALYTIC HYDROGENATION, TREATING WITH THIOCYANIC ACID | SYNTEX (U.S.A.) INC. (US) | 1998-02-17 | — | — | US | disclosed |
| EP-0757677-A1 | BENZOCYCLOALKYLAZOLETHIONE DERIVATIVES | SYNTEX (U.S.A.) INC. (US) | 1997-02-12 | — | — | EP | disclosed |
| US-5538988-A | CARDIOVASCULAR DISORDERS AND DOPAMINE HYDROLASE ENZYME INHIBITORS | SYNTEX (U.S.A.) INC. | 1996-07-23 | — | — | US | disclosed |
| WO-1995029165-A2 | BENZOCYCLOALKYLAZ0LETHIONE DERIVATIVES AS DOPAMIN BETA-HYDROXYLASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1995-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404265-B2 | Substituted pyridine derivatives as SARM1 inhibitors | SARM1, SARNP, ADRM1 | FFAR1 4246/4885FFAR4 4580/4885KEAP1 534/4885 |
| US-11970481-B1 | Substituted pyridine derivatives as SARM1 inhibitors | SARM1, SARNP, ADRM1 | FFAR1 4246/4885FFAR4 4580/4885KEAP1 534/4885 |
| US-11952370-B2 | Selective ligands for modulation of GIRK channels | GRIK4, GRIK2, GRIK1 | FFAR1 1152/4885FFAR4 772/4885KEAP1 822/4885 |
| US-20240116901-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | SARM1, SARNP, ADRM1 | FFAR1 4246/4885FFAR4 4580/4885KEAP1 534/4885 |
| US-11999695-B2 | YAP1 inhibitors that target the interaction of YAP1 with OCT4 | YAP1, YES1, MYC | FFAR1 4636/4885FFAR4 4428/4885KEAP1 1276/4885 |
| US-20240199591-A1 | SELECTIVE LIGANDS FOR MODULATION OF GIRK CHANNELS | GRIK4, GRIK2, GRIK1 | FFAR1 1152/4885FFAR4 772/4885KEAP1 822/4885 |
| US-12037333-B2 | Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication | PLPBP, EIF2AK2, TYMP | FFAR1 4827/4885FFAR4 4791/4885KEAP1 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.